Researchers have developed a novel system of gene therapy that targets lung stem cells to treat cystic fibrosis. By using a natural compound found in the lungs, the therapy enables airway cells to take up the therapeutic gene and shows substantial recovery from the disease defect.
Researchers have developed a gene therapy technique that integrates DNA without using viral vectors, inserting the DNA at known locations. The technique successfully integrated a gene coding for Factor IX into mouse DNA, making 12 times more protein than control mice.
A new study using gene therapy has shown promise in treating Parkinson's disease by 'resetting' overactive brain cells. The therapy may arrest or delay disease progression, offering a safer and more powerful alternative to current treatments.
Researchers discovered a gene, Hsp27, that protects mature nerve cells from death following injury. Delivering this gene via therapy may lead to new treatments for neurodegenerative diseases and nerve injuries.
Researchers have successfully delivered the full-length dystrophin gene to mice with muscular dystrophy using stripped-down vectors, restoring normal muscle function. The breakthrough could pave the way for human clinical trials to assess the safety of this method in patients.
A novel gene therapy technique developed by Stanford researchers allows for the integration of large genes into human chromosomes, enabling continuous production of proteins. This technique has the potential to treat a variety of diseases, including Duchenne's muscular dystrophy and cystic fibrosis.
Researchers have developed a gene therapy approach to treat mucopolysaccharidosis VII, a disorder affecting multiple organ systems, in dogs. The treatment involves four intravenous injections of a retroviral vector expressing canine beta-glucuronidase, resulting in normal enzyme activity and near-normal mobility in treated dogs.
Researchers developed a gene therapy combining radiation therapy and cisplatin to target tumor cells, resulting in significant regression with no additional toxicity. The treatment uses a modified cold virus to insert the TNF gene into tumor cells, enhancing anti-cancer effects.
Researchers at Stanford University Medical Center have developed a gene-therapy technique that can switch off genes in mice using RNA inhibition. The method has shown promising results in reducing light production from a firefly gene, suggesting its potential use in treating diseases such as cancer and hepatitis C by deactivating virus...
Researchers at Penn State College of Medicine have discovered that a protein previously thought to be in the nucleus resides in the cytoplasm, correcting a scientific theory since 1992. This finding offers new parameters for understanding gene switches and their role in human diseases.
A new gene therapy tool has shown promising results in treating mice with hemophilia A by correcting the faulty factor VIII gene. The technology uses RNA trans-splicing to produce normal factor VIII protein, offering a potential cure for this genetic disorder.
Researchers suggest that drugs blocking the ICAM1 gene could reduce lung scarring caused by radiation therapy, potentially improving patients' breathing and exercise abilities. In a study, mice lacking this gene showed improved pulmonary function tests and reduced fibrosis, indicating inflammation's role in lung scarring.
Researchers have successfully used a virus that causes warts to restore LDL receptor function in cells with defective genes, offering new hope for treating familial hypercholesterolemia. The next step is testing this technique in animals and humans to determine its safety and effectiveness.
Researchers have identified a human gene that appears to be the counterpart to the mouse Mater gene, essential for fertilized egg development. The discovery may lead to new approaches in studying and treating female infertility, as well as understanding the role of the immune system in premature ovarian failure.
A new study shows that VNS Therapy is more effective in treating epilepsy patients when used earlier in their treatment course, resulting in a three-fold improvement in seizure control. The therapy also improves quality of life indicators such as alertness, mood, and verbal communications.
Researchers found that women with a common mutation in the estrogen receptor alpha gene had dramatic increases in high-density lipoprotein (HDL), or the 'good' cholesterol. This discovery suggests that genetic testing may help doctors make better decisions about hormone replacement therapy for preventing heart disease.
A new intracoronary gene therapy has shown promising results in treating stable angina, a condition affecting nearly 7 million people nationwide. The study, led by the University of Vermont, involved 79 patients and demonstrated improved exercise ability compared to placebo groups.
Gene therapy has shown promising results in hemophilia trials, with patients experiencing significant improvements in quality of life. The treatment involves inserting a normal version of the defective gene to produce clotting factor, and has been tested in small animals before being moved to human trials.
Researchers at Northwestern University have developed a gene therapy that reduces inflammatory cytokines involved in joint inflammation. The treatment, which uses the IL-13 gene, has been shown to suppress joint inflammation and prevent the development of arthritis in rat models.
Researchers discovered that the Rad54 gene plays a vital role in repairing DNA breaks in a neat and efficient manner, preventing mutations. The study's findings suggest that individuals without this gene may be more susceptible to radiation therapy side effects and could benefit from milder treatment protocols.
Researchers have developed a gene therapy using human blood outgrowth endothelial cells to treat hemophilia A. The treatment, which has shown long-term attainment of robust levels of factor VIII, is promising and may pave the way for testing in humans.
Scientists have successfully genetically altered human blood stem cells to selectively activate genes in developing immune cells, providing a potential breakthrough for gene therapy. The research uses a lentivirus to transfer a fluorescent protein gene into stem cells, which then express the gene only in specific immune cells called an...
A new gene therapy method has successfully corrected sickle cell disease in mice by transferring an anti-sickling gene to bone marrow, preventing the formation of deformed red blood cells. The therapy, developed using a viral delivery system, resulted in up to 99% expression of the new gene in circulating red blood cells.
Scientists have successfully corrected sickle cell disease in mice using gene therapy by introducing an anti-sickling human beta-hemoglobin gene. The study, supported by the NHLBI, shows promising results with high expression of the gene in up to 99% of circulating red blood cells.
The UNC-Chapel Hill Gene Therapy Center will use the funds to translate basic research knowledge into safe human clinical trials, with a focus on cystic fibrosis and hemophilia. The center aims to provide new treatments for diseases caused by single-gene defects.
In two studies, VEGF gene therapy significantly reduced angina episodes and improved exercise tolerance in patients with end-stage coronary heart disease. The treatment has shown impressive clinical results, with most patients experiencing continued improvement in daily life after treatment.
A new 'double suicide gene' therapy has shown promise in treating prostate cancer by carrying pairs of fused genes directly into cancer cells and inducing self-destruction. The technique achieved "greater levels of targeted cytotoxicity" than single suicide gene therapy, with minimal toxicities reported among patients.
Researchers at the University of Wisconsin-Madison have made a breakthrough in gene transfer technology by inserting a jellyfish gene into rhesus monkey embryos, resulting in transgenic placentas that produce the desired protein. The study promises new insights into pathologies of pregnancy and has implications for human gene therapy.
Researchers have successfully used gene therapy to reduce new blood vessel growth by up to 90% in mice with conditions similar to macular degeneration and diabetic retinopathy. Two genes, endostatin and pigment epithelium-derived factor (PEDF), were injected into the animals' eyes or tails to demonstrate the potential of gene therapy a...
Researchers used gene therapy to treat mice with beta-glucuronidase deficiency, a condition that affects approximately 1 in 5,000 babies. The treatment showed promise by improving symptoms for up to a year, but six mice eventually developed cancer, raising questions about the long-term safety of this approach.
Researchers have discovered a potential cause of male infertility, identifying the ZNF214 gene as a candidate gene. The gene is linked to impaired spermatogenesis and may be inherited from mothers. Further research will help understand its role in sperm production and develop targeted treatments.
Scientists at UNC Health Care have successfully used gene-therapy to produce high amounts of a clotting protein in animals, bypassing a major hurdle for treating hemophilia. The new method could potentially yield sustained factor IX production in humans, eliminating the need for daily injections.
Scientists at the University of Pittsburgh have engineered a novel gene therapy to treat Duchenne Muscular Dystrophy (DMD), a genetic disorder causing progressive muscle weakening and death. The mini-gene AAV vector effectively delivers functional dystrophin protein, correcting muscle dysfunction and degeneration.
Researchers developed a tissue culture system that mimics normal cell growth, allowing them to study gene transfer techniques in greater detail. They found that cancer cells can be easily infected while normal cells are poorly infected, suggesting a potential target for gene therapy.
A follow-up study of the VEGF in Ischemia for Vascular Angiogenesis (VIVA) trial found that gene therapy did not increase the risk of cancer or adverse events in patients with severe angina. The results showed a lower rate of adverse events in patients receiving the high-dose VEGF, and encouraging reductions in chest pain after one year.
A new gene therapy technique using stents with DNA delivery has shown promise in animal studies for treating coronary artery disease. The method uses a biodegradable film to release genes into cells on the artery wall, inhibiting cell growth and potentially preventing further damage.
Researchers at Thomas Jefferson University have developed a new gene therapy system that uses DNA and bacterial proteins to deliver genes to specific places in human DNA, avoiding viruses and their associated immune reactions. The technique shows promise for treating genetic diseases such as hemophilia and sickle cell anemia.
Researchers at Jefferson Medical College successfully introduced a therapeutic gene into the brain of two children with Canavan disease, showing decreased NAA concentration and increased myelin. The gene transfer demonstrated positive neurological improvements in the patients, offering hope for future use of gene therapy for brain dise...
Researchers at Duke University Medical Center have successfully used a heat-sensitive gene to slow down tumor growth in mice by 300-400 times over baseline. The gene therapy, which uses hyperthermia, also boosts the immune system's ability to fight cancer.
A genetically stripped down HIV-based vector has been developed that can deliver genes to target cells in the body safely. The vector can also be turned off with a common antibiotic, which suggests doctors may one day be able to control gene expression in people treated with HIV-based gene therapy vectors.
Dusty Miller, PhD, received the National Hemophilia Foundation's 1999 Dr. Murray Thelin Researcher of the Year Award for his work on gene therapy, a potential treatment for hemophilia. His pioneering research has led to the development of retroviral gene-transfer kits and promising early-stage gene-therapy trials.
Targeted Genetics Corporation has shown promise in its AAV gene therapy program for rheumatoid arthritis (RA), reducing ankle and hind paw swelling in preclinical studies. The treatment uses a recombinant TNFR:Fc fusion protein, which antagonizes the function of TNF-a, a key component of the inflammatory response.
French researchers develop gene therapy to treat human severe combined immunodeficiency (SCID) X1, a life-threatening disease. Two infants experience 'striking' clinical improvements and return to normal immune system functioning without side effects.
Researchers from Massachusetts General Hospital report that delivering extra copies of the SERCA2a gene to the heart muscle via gene therapy techniques alleviates diastolic dysfunction in aging rats. This study provides a potential target for therapies to prevent progression to heart failure.
Researchers have developed an antitat gene therapy that blocks HIV replication in cells from infected patients, prolonging survival of immune system cells and potentially maintaining the virus in a dormant state. The approach combines genetic engineering and antisense technology, offering a promising new strategy for treating AIDS.
Researchers at Thomas Jefferson University have used gene therapy to replace a damaged Rb2 gene with a healthy version, dramatically shrinking lung cancer tumors in mice. The study provides direct evidence that Rb2 is a tumor suppressor and demonstrates its potential as a target for human gene therapy trials.
A team of UI researchers has advanced understanding of how gene therapy might effectively treat cystic fibrosis by addressing two fundamental problems: inefficient gene transfer and lack of gene persistence. They demonstrated efficient and lasting gene transfer into airway cells using a new vector from the retrovirus family, feline imm...
Researchers from Children's National Medical Center and University of Pittsburgh successfully reverse muscle damage caused by limb girdle muscular dystrophy using gene therapy. The non-toxic virus-based approach increases muscle strength and size by nearly 100% in animal tests, paving the way for potential treatment of Duchenne muscula...
Researchers have discovered a genetic on-off switch in yeast that could be used to control insulin levels in diabetics. The switch, consisting of two main parts, can be turned on or off by adding a chemical inducer, allowing for tight control over gene expression.
Researchers identified a possible new tumor-suppressor gene that plays a role in colon cancer and may predict response to new cancer therapy. The gene produces a protein important for fat cell maturity and metabolism, and its mutations may make tumors more susceptible to the antidiabetes drug troglitazone.
Researchers at Northwestern University have halted motor neuron destruction and slowed ALS progression using GDNF gene therapy in laboratory mice. The approach may one day prove effective in treating humans with ALS.
Scientists identify a key gene responsible for pain sensitivity, revealing potential for tailored pain medications and predicting addiction risk. The study's findings suggest that individual genetic variations in the mu opiate receptor gene can affect pain perception and response to morphine.
New gene therapy study in mice demonstrates a gradual increase in factor VIII levels, stable for 11 months. The goal is one dose, which could be all that's needed to be physiologically cured of future bleeds.
Researchers at UPMC have successfully conducted the world's first in vivo gene therapy for hemophilia A using a modified retrovirus to deliver the FVIII gene. The treatment aims to permanently restore clotting factor production, reducing costs and complications associated with the disease.
Gene therapy's concern about viral DNA insertion into gametes is unfounded, as naturally occurring insertions in sperm cells are 100 times more common than the FDA limit. Researchers estimate that 1 individual in every 8 carries a new retrotransposon insertion.
The American Society of Gene Therapy is hosting its 2nd Annual Meeting, featuring key researchers and NIH director Harold Varmus. The event showcases the latest advancements in gene therapies for various genetic disorders, including AIDS, cardiovascular disease, cancer, cystic fibrosis, and neuromuscular diseases.
Researchers have successfully delivered beta-endorphin genes into the sheath of tissue surrounding the spinal cord, reducing hyperalgesic pain sensation in animal models. The study's simplified approach and selective therapeutic effect suggest potential applications for treating various spinal cord and brain disorders.
Researchers David Kirk and Stephen Miller have discovered a transposon gene, called Jordan, in the green alga Volvox. This gene helps them isolate genes of interest to understand their form and function, shedding light on cell reproduction and specialized cells. The study has implications for human gene therapy and cancer research.
Researchers have successfully tested a new gene therapy approach to block certain pain responses in mice. The treatment uses a herpes virus containing a gene that triggers production of a pain-blocking protein, providing long-term potential for pain relief.
A study by Johns Hopkins Medicine reveals that nearly 90% of prostate cancers are linked to a common genetic process called 'gene switching,' which can be reversed with drugs. This finding has the potential to correct one of the most common cancers in men without using typical gene therapy.